Glycopyrrolate/indacaterol/mometasoneAlternative Names: ICS/LABA/LAMA inhaled triple therapy - Novartis; QVM 149
Latest Information Update: 12 Nov 2016
At a glance
- Originator Novartis
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Corticosteroids; Glucocorticoids; Indans; Pregnadienediols; Pyrrolidines; Quaternary ammonium compounds; Quinolones; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Asthma
Most Recent Events
- 05 Oct 2015 Novartis plans a phase III trial for Asthma in Estonia, Germany, Lithuania and Thailand (NCT02571777)
- 18 Jun 2015 Early research in Asthma in USA (Inhalation)